Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), ...

Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar ...

Outcomes in the lamivudine group were compared with those in a historical cohort of individuals who received aflibercept, bevacizumab, or ranibizumab. Continual intravitreous administration of ...

Dilsher S. Dhoot, MD discusses how newer anti-VEGF treatments, particularly aflibercept 8mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular AMD ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched ...

Alvotech and Advanz Pharma previously entered into partnership agreements, signed in 2023, to commercialize proposed biosimilars to Xolair® (omalizumab), Simponi® (golimumab), Entyvio® (vedolizumab), ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

has adopted a positive opinion recommending the label extension for Eylea 8 mg (aflibercept) in the EU. This extension will enable longer treatment intervals, up to six months, for two major ...

Eylea 8 mg is already approved in more than 50 markets, and further regulatory submissions are under review in additional countries. In the EU and U.K., Eylea 8 mg is the only anti-VEGF treatment ...

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular ...